NABI BIOPHARMACEUTICALS Registration Rights AgreementRegistration Rights Agreement • May 25th, 2005 • Nabi Biopharmaceuticals • Biological products, (no disgnostic substances) • New York
Nabi Biopharmaceuticals, a Delaware corporation (the “Company”), proposes to issue and sell to the Purchasers (as defined herein) on the terms set forth in the Purchase Agreement (as defined herein) its 2.875% Convertible Senior Notes due 2025 (the “Securities”). As an inducement to the Purchasers to enter into the Purchase Agreement and in satisfaction of a condition to the obligations of the Purchasers thereunder, the Company agrees with the Purchasers for the benefit of themselves and the Holders (as defined herein) from time to time of the Registrable Securities (as defined herein) as follows:
